Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03683251 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Study acronym: Portal
StatusRecruiting
PhasePhase 3
Started2018-09-20
View on ClinicalTrials.gov ↗
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.

Amendment history 2 changes detected by DataLookout

2026-06-05
Primary completion pushed: 2029-10-31 → 2029-12-31
2026-06-05
Completion pushed: 2029-10-31 → 2029-12-31
Trial Details
NCT Number NCT03683251
Lead Sponsor Hoffmann-La Roche
Conditions Neovascular Age-Related Macular Degeneration
Enrollment 1,000 participants
Start Date 2018-09-20
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-31